SpeedScreen is a novel, label-free, in-solution, affinity-based selection methodology for high-throughput screening (HTS) developed at Novartis Pharma. The SpeedScreen protocol comprises in-solution affinity selection, followed by size exclusion chromatography in combination with microbore-liquid-chromatography/electrospray-ionization mass spectrometry (micro-LC/ESI-MS). The authors describe the basic concept behind assay development, HTS, and data analysis with the SpeedScreen technology. Advantages and limitations of SpeedScreen compared to alternative screening technologies are discussed, and an example is given from a SpeedScreen campaign applying this innovative affinity selection concept in HTS.
INTRODUCTION
T HE CURRENT DRUG DISCOVERY PROCESS relies on massive screening of chemical libraries and natural products against various biochemical and cell-based targets for the identification of new drug-like compounds. With the advent of genomics, deciphering the human genome 1 has generated a large number (> 40%) of new molecular targets with unknown function (orphan targets), as well as a large number of molecular targets with known function, which are, however, nontractable for automated high-throughput screening (HTS). It is anticipated that in the near future, a burst of new, partly characterized genes will necessitate new strategies for target finding, target selection, and, in particular, HTS. Taken together, this raises the question as to what extent and by which technology we will be able to address orphan or nontractable targets for HTS.
In chemical genomics, chemistry provides the necessary chemical space (compounds) by means of medicinal and combinatorial chemistry, as well as natural products. Genomics provides the necessary biological space and molecular targets, with sufficient evidence to launch lead finding and screening programs. The most straightforward combination of chemical and biological space is addressed by affinity selection methods, which identify chemical binders to biomolecules, ideally independent of functional information on the biological target. Affinity selection has to distinguish between target-bound and unbound chemical compounds and has to deliver a format for the identification of the binders. Two formats are generally applicable for affinity selection: in the heterogeneous format (Fig. 1A) , the target is immobilized on an activated surface. Unbound compounds are removed in 1 or several washing steps, which has the disadvantage that only high-affinity binders remain associated with the target. In the homogeneous format ( Fig. 1B) , the target and the compounds are combined in solution. To separate bound from unbound compounds, fast size exclusion chromatography can be applied, for example, allowing even the detection of low-affinity binders.
Novartis Pharma has developed a new affinity selection-based methodology, termed SpeedScreen, especially for HTS of orphan and nontractable targets. Following in-solution affinity selection, we apply size exclusion chromatography (SEC) in combination with microbore-liquid-chromatography/electrospray-ionization mass spectrometry (micro-LC/ESI-MS) to identify binders. SpeedScreen is currently among the most straightforward approaches for drug discovery on genomic targets with unknown biological function or unknown screening format (orphan targets). Details of the SpeedScreen methodology were recently published in detail. 2 In the following, we briefly describe the basic concept behind assay development, HTS, and data analysis with the SpeedScreen technology. We shall focus on the application of SpeedScreen, ad-vantages and limitations of the technology, and its comparison to alternative screening technologies. Finally, we give an example from one of our screening campaigns in which we have successfully used this HTS concept.
MATERIALS AND METHODS

Primary screening procedure
Incubation A total of 0.5 µL of the compound pool solution in DMSO is transferred to each of the 88 wells of a 96-well microtiter plate (MTP) (e.g., Multiscreen-HA, MAHAN4510, Millipore, Bedford, TX), followed by the addition of 24.5 µL of the target protein in buffer. Eight wells per plate remain free for control samples. In the final volume of 25 µL, each compound has a concentration of 7 µM, and the protein concentration is 10 µM. The final DMSO concentration is 2% (v/v). The plate is then sealed and the mixture incubated for 1 h at ambient temperature.
Separation of bound from unbound compounds
After incubation of the MTP to achieve full binding of all compounds in equilibrium, the content of each well is transferred to a 96-well format SpeedScreen "sandwich," consisting of a loading MTP with pinholes in the well bottoms (MDS Protana, Denmark), a size exclusion plate, and a collection plate. The pinhole MTP is situated on top of the SEC MTP (AutoSeq96 ™ , Amersham Pharmacia Biotech, Switzerland), which contains the premanufactured and equilibrated size exclusion gel (Sephadex ™ G50). A collection MTP is added underneath the SEC MTP to complete the SpeedScreen sandwich. The sandwich is loaded into the carriers of a centrifuge (5810 R, Eppendorf, Germany) and run at 910g for 2 min at 4°C.
Disintegration of binder-protein complex and detection of binders by LC/MS
After SEC, the collection plates are transferred to the refrigerated (10°C) drawers of the CTC PAL sample injector. From each MTP well, 5 µL is injected onto a Reprosil PUR 300 ODS-3 highperformance liquid chromatography (HPLC) column (1 mm × 30 mm, 300 Å, Dr. Maisch AG, Switzerland). The column is eluted with an acid organic solvent gradient from 5% to 95% acetonitrile within 10 min runtime to disintegrate the target-binder complex. The column effluent is directed to the electrospray (ESI) ion source of the mass detector, which is monitored in full-scan positive ion mode.
Binder identification
Ligands to the target protein are identified by comparison of their m/z value (mainly, molecular mass + H or Na) with the molecular masses of the 400 compounds from that particular well.
Confirmation and control screening
Hits from the primary screening are picked as single compounds and incubated with the target protein (10 µM) in the confirmation screening as 7-or 10-µM solutions in DMSO. The same protocol as described for primary screening is applied. After picking of the binders from the confirmation screening, a final control screening is performed following the same procedure as applied to the confirmation screening but in the presence and absence of the target, respectively. All incubations in the control screening are done in triplicate.
The whole SpeedScreen procedure is schematically summarized in Figure 2 .
RESULTS AND DISCUSSION
The SpeedScreen technology is a novel HTS technology for "genomic" and "nontractable" HTS targets, which is very straight-
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forward and easy to upset ( Fig. 3 ). Using the 96-well format, the only instruments required are a temperature-controlled centrifuge and an LC/MS system consisting of a gradient HPLC pump with an online eluent degasser, a temperature-controlled automated sample injector, and an ion trap mass spectrometry detector. For a technology with sequential mass spectrometry readout, highthroughput conditions can only be reached when using pooled compound libraries in the primary screening. With pools of 400 compounds in each of 88 wells per 96-well MTP, a total of 35,200 compounds per MTP are available for screening. The remaining 8 wells can be filled, for example, with control substances. As was shown in previous investigations 2 with pool sizes ranging from 100 to more than 1000 compounds per well, a pool of 400 compounds represents an optimal complexity. A smaller pool size would decrease the throughput efficiency, whereas a higher pool size might impair compound solubility and increase the risk for chemical cross-reactivity of the compounds. With compound pools above 400, we observed an increase in false positives by means of compounds detected in the SEC eluate also in the absence of the target protein. Corresponding MS spectra point to the formation of compound aggregates and caused the appearance of substances with high molecular mass, which were different from the mass of any of the single compounds. Upon addition of the 24.5-µL buffered target solution to the 0.5-µL DMSO solution of the compound pools, opacity became visible for larger pool sizes than 400 compounds per well. This appeared to be dependent on the buffer composition. Designed pool mixtures could be a means to avoid the observed restrictions in pool sizes. With a pooled compound approach, com-petition of several ligands at the binding site(s) of a target is possible. As any competition will decrease the concentration of a binder during the separation of target-bound from unbound compounds, a sensitive mass detector is needed that allows for full-scale mass detection without substantial loss in sensitivity. This is most favorably covered by an ion trap MS detector. 3 For MS sensitivity but also for protein and compound consumption reasons, a target concentration of 10 µM and compound concentrations of 7 (primary screening) or 10 µM (confirmation and control screening) and an incubation volume of 25 µL were assessed. The DMSO concentration in the incubation mixture does not exceed 2%, which is compatible with the vast majority of proteins and appears sufficient to keep the compounds in solution. The conditions for incubation of a primary screening are shown in Figure 4 .
Following incubation of target protein with pools of 400 compounds per well, fast separation of bound from unbound compounds is the crucial step of the SpeedScreen technology. For that purpose, we use SEC with either commercially available or homemade Sephadex ™ gel-filled SEC 96-well plates in our SpeedScreen sandwich (see Fig. 3 ). Investigations on the minimal duration of centrifugation showed that about a 10-sec centrifugation at 910g is sufficient to separate high-molecular from low-molecular mass components. Subsequent disintegration of the target-binder complex is achieved during the reversed-phase chromatography step by gradually increasing the organic solvent (acetonitrile) content of the mobile phase under acidic conditions (formic acid). Even high-affinity binders such as staurosporine (K D < 1 nM), a ligand of protein kinases, 4 can be disintegrated from the kinase under the conditions applied in SpeedScreen. We use a tandem column-switching device to reduce total chromatography runtime. One column is equilibrated with the starting conditions during the elution of the second column. After completion of the reversed-phase chromatography, compounds and protein are detected by MS with electrospray ionization in full-scan positive ion mode. The detection of the protein together with the compounds is important, as any compound observed in the absence of protein would point to its artificial elution from the SEC gel as a higher order aggregate (false positive). The feasibility to detect single compounds with the SpeedScreen technology was shown, for example, with ligands of protein kinase A (PKA, E.C. 2.7.1.37). Olomoucine (IC 50 = 3-7 µM), staurosporine (K D < 1 nM), and a Novartis compound (CHC12844708) were incubated with PKA following the protocol described above. After SEC and LC/MS, the mass chromatograms shown in Figure 5 were obtained with a mass peak corresponding to the respective protonated compound (M + H). No mass peak could be detected if PKA was absent during incubation. These data show that also less affine compounds to PKA, such as olomoucine, can be detected as binders with the SpeedScreen technology. Additional information came from secondary assays with enzyme targets. Hits from several SpeedScreen campaigns were used to de-termine IC 50 values. We were able to detect inhibitors (binders) at IC 50 values up to the double-digit micromolar concentration. To test the feasibility of affinity ligand detection in a complex pool of compounds, 400 Novartis compounds at a final concentration of 7 µM each were spiked with staurosporine (7 µM) and incubated with PKA (10 µM). After incubation for 1 h with and without the kinase and submission to fast SEC, the mass chromatogram without PKA showed 1 peak at about a 3-min retention time in both samples and also in a chromatogram obtained prior to SEC. Only in the presence of PKA did the mass chromatogram show a large additional peak at 10.73 min retention time (Fig. 6) . Obviously, the peak eluting at 3 min is a matrix peak, whereas the peak detected at 10.73 min corresponds to staurosporine, as confirmed by the underlying mass spectrum (data not shown). This example demonstrates the feasibility of the SpeedScreen technology to specifically detect an affinity ligand for a given target, even if such a compound is part of a complex mixture of several hundred chemicals.
Missing Link between Genomics and Lead Discovery
The SpeedScreen HTS technology has been applied in Novartis lead discovery to screen various targets, such as transcription factors, adapter molecules, regulatory subunits, heat shock proteins, metal binding proteins, RNA binding proteins, transferases, dehydrogenases, kinases, isomerases, proteases, phosphatases, oxidoreductases, and many more. No differences were observed for the applicability of SpeedScreen between the different types of targets or related to their molecular size. We have even used heterodimeric proteins successfully. Only when looking for proteinprotein interactions have we found a significantly smaller number of binders compared to other targets. We recommend using soluble, globular proteins for SpeedScreen. In Table 1 , the data for a SpeedScreen campaign with an ubiquitin-conjugating enzyme 5 (E2 family), purified to homogeneity (> 95% purity), are summarized. An enzyme target was selected because follow-up assays, such as inhibition of thiolester formation, are available to characterize the SpeedScreen binders. A compound library of 457,600 compounds was submitted to the primary SpeedScreen with pooled compounds. The hit list of 151 compounds for this target is at the lower end of primary hit rates in SpeedScreen, which is dependent on the target and typically ranges between 0.05% and 1.5%. After confirmation and control screens with single com-pounds, 23 hits were confirmed for that target. Most of these compounds could be shown to inhibit the thiolester formation in a subsequent secondary enzymatic assay with low micromolar IC 50 values (data not shown here), demonstrating binding of the ligands to the catalytic center of the enzyme.
The present setup and conditions of SpeedScreen with a 10-min injection cycle allow for analysis of 6 samples per hour or 144 samples per day, translating into 57,600 (144 × 400) compounds per day. As many as 403,200 compounds can be analyzed per week with unattended LC/MS runtime. Hence, for a primary screening campaign of a 500,000-compound library with SpeedScreen, about 9 days are needed. Protein consumption for a target with a molecular mass of 25,000 Da is 12.5 mg. The corresponding compound consumption is 175 pmoles for nonbinders and 1.4 nmoles for binders due to the additional confirmation plus control screenings, with triplicate assays in the presence and absence of the target for the latter. The cost for a whole SpeedScreen campaign is below U.S.$10,000 (excluding cost for lab infrastructure, depreciation, and personnel), and its duration is about 4 weeks.
SpeedScreen was especially developed to screen orphan targets, for which no alternative to affinity-based screening is available. SpeedScreen is also perfectly suited for targets lacking a functional assay for HTS. Compared to technologies using a heterogeneous format, the homogeneous in-solution technology of SpeedScreen is able to detect ligands with even a relatively low affinity to the target. This was demonstrated for the inhibition of an ubiquitin-conjugating enzyme by the IC 50 values up to the 2-digit micromolar range but also by secondary assays with other enzyme targets. Limits in the detection of low-affinity binders are most likely related to the selection of low k off rate binders in the SEC step. After several dozens of screening campaigns, we have performed more thorough kinetic and thermodynamic studies for some of these binders, which again showed that we can detect binders with a double-digit micromolar affinity. Besides the ability to find binders to the active center of an enzyme or to an agonist/ antagonist binding site of a receptor, SpeedScreen can also detect binders to allosteric binding sites or to other binding sites on a protein that are not covered by a functional screening assay. The technology was successfully applied to compounds with a relatively broad range of molecular mass and polarity from all sources (i.e., medicinal chemistry, combinatorial chemistry, and natural products). This makes SpeedScreen a valuable HTS technology, which is complementary to other HTS platforms with a functional approach. Limitations of SpeedScreen are the appearance of false positives in primary screening due to the single-stage mass spectrometry readout. Structurally different molecules with the same m/z value cannot be differentiated with single-stage MS and need to be picked all together for the subsequent confirmation screen. Designed compound pools would be a way out of this drawback. Another restriction is that only positively charged compounds can be detected using an acidic mobile phase in the reversed-phase chromatography step and positive ion monitoring in the mass detector. Fewer than 15% of the library compounds are not positively charged under these conditions or belong to a small fraction of neutral compounds. We conclude a very low number of false negatives below 5% for any target. Despite these limitations, the hit validation in the final control screen is highly consistent. In the triplicate singleton analysis with and without the target, respectively, a binder is only considered validated if it was detected 3 times in the presence of the target. These binder compounds are unambiguously confirmed by their mass signal in our setup. Taken together, under the conditions currently applied for SpeedScreen at Novartis Pharma AG, it is highly unlikely to find false positives. Due to its short turnaround time, its extremely cost-effective properties, and its success with various target classes, SpeedScreen has become a proven technology for lead discovery at Novartis Pharma AG. It is mainly applied for HTS campaigns with orphan targets but also for those with nontractable targets and any targets for which the focus is on ligands that do not affect functional activity.
